Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Outcomes After PSMA PET-Staged Comprehensive Progression-Directed Radiotherapy for Limited Progression in Prostate Cancer: An Ambispective Multicenter Registry With a Prospective 1-10-Metastasis Cohort

NCT07691697 is registered in ClinicalTrials.gov with Affidea Nu-med Center of Oncological DIagnostics and Therapy as lead sponsor.

NCT NCT07691697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07691697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Outcomes After PSMA PET-Staged Comprehensive Progression-Directed Radiotherapy for Limited Progression in Prostate Cancer: An Ambispective Multicenter Registry With a Prospective 1-10-Metastasis Cohort
Lead sponsor
Affidea Nu-med Center of Oncological DIagnostics and Therapy
Phase
Observational
Overall status
Recruiting
Start date
June 26, 2026
Completion date
December 30, 2031
Enrollment
1,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer, oligoprogressive prostate cancer